Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

NCT06911710 is registered in ClinicalTrials.gov with Tianjin Medical University General Hospital as lead sponsor.

NCT NCT06911710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06911710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
Lead sponsor
Tianjin Medical University General Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 9, 2024
Completion date
February 28, 2027
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml (acute myelogenous leukemia), b-all, lymphoma, b-cell, aggressive non-hodgkin (b-nhl), myeloma multiple, t-all/lymphoma, t-lymphocyte lymphoma